January 4, 2017 10:37 AM ESTUpdated 11:36 AM
People

For­mer No­var­tis phar­ma­ceu­ti­cals chief David Ep­stein is go­ing biotech

John Carroll

Editor & Founder

David Ep­stein is join­ing a long line­up of ex­ecs who are ex­chang­ing Big Phar­ma ti­tles for a promi­nent place in the biotech world. The for­mer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

FDA plans to ban phar­ma em­ploy­ees from serv­ing on ad­comms. The im­pact will be lim­it­ed

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times